Alnylam to Webcast Conference Call Discussing 2006 Financial Results.CAMBRIDGE, Mass. -- Alnylam Pharmaceuticals Alnylam Pharmaceuticals Inc. (NYSE: ALNY), a biopharmaceutical company, engages in the development and commercialization of therapeutic products based on RNA interference (RNAi) in the United States. , Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, today announced that it will report financial results for the fourth quarter and year ending December 31, 2006 on Wednesday, February 7, 2007, after the U.S. financial markets close. Management will provide an update on the company, discuss fourth quarter and year end results, and discuss expectations for the future via conference call on Wednesday, February 7, 2007, at 4:30 p.m. ET. To access the call, please dial 800-299-7928 (domestic) or 617-614-3926 (international) five minutes prior to the start time and provide the passcode 79614148. A replay of the call will be available from 6:30 p.m. ET on February 7, 2007 until February 14, 2007. To access the replay, please dial 888-286-8010 (domestic) or 617-801-6888 (international), and provide the passcode 94382017. A live audio webcast of the call will also be available on the "Investors" section of the company's website, www.alnylam.com. An archived webcast will be available on the Alnylam website approximately two hours after the event and will be archived for 14 days. About Alnylam Alnylam is a biopharmaceutical company developing novel therapeutics based on RNA interference RNA interference n. A process in which the introduction of double-stranded RNA into a cell inhibits the expression of genes. , or RNAi. The company is applying its therapeutic expertise in RNAi to address significant medical needs, many of which cannot effectively be addressed with small molecules or antibodies, the current major classes of drugs. Alnylam is building a pipeline of RNAi therapeutics; its lead program is in Phase I human clinical trials for the treatment of respiratory syncytial virus respiratory syncytial virus (sĭnsĭsh`əl): see cold, common. (RSV RSV respiratory syncytial virus; Rous sarcoma virus. RSV abbr. respiratory syncytial virus RSV 1 Respiratory syncytial virus, see there 2 Rous sarcoma virus, see there ) infection, which is the leading cause of hospitalization in infants in the U.S. The company's leadership position in fundamental patents, technology, and know-how relating to relating to relate prep → concernant relating to relate prep → bezüglich +gen, mit Bezug auf +acc RNAi has enabled it to form major alliances with leading companies including Merck, Medtronic, Novartis, and Biogen Idec Biogen Idec, Inc. (NASDAQ: BIIB) is a biotechnology company specializing in drugs for neurological disorders, autoimmune disorders and cancer. The company was formed in 2003 by the merger of Cambridge, Massachusetts-based Biogen and San Diego, California-based Idec . The company, founded in 2002, maintains global headquarters in Cambridge, Massachusetts, and has an additional operating unit operating unit A type of operating company that engages in transactions with outsiders and that is owned by another business. For example, in 1995 the stockholders of Capital Cities/ABC approved a $19 billion merger with the Walt Disney Company, whereupon in Kulmbach, Germany. For more information, visit www.alnylam.com. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion